Antibody discovery moves toward de novo design From computationally designed repertoires to AI-driven specificity prediction and multispecific therapeutics, antibody researchers are developing new ways to design molecules for the biology they need to influence. Written byBree Foster, PhD and Andrea Corona

Antibody discovery moves toward de novo design From computationally designed repertoires to AI-driven specificity prediction and multispecific therapeutics, antibody researchers are developing new ways to design molecules for the biology they need to influence. Written byBree Foster, PhD and Andrea Corona https://www.drugdiscoverynews.com/antibody-discovery-moves-toward-de-novo-design-17541?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9Qcy62gGqVoCB1arOfC3hVcscePxYUMwVMX6d0jxbcxdo_MSZ8WTV3u8VGdR8BHdt2r3ID73ba_PLH99Fkxw766IBMug&_hsmi=441645340&utm_content=441645340&utm_source=hs_email What if researchers could design antibodies with specific biological functions rather than simply search for molecules that bind a target? That question ran through The Antibody Series 2026 (TAS 2026), where speakers explored how computational design, AI, and increasingly complex antibody formats could expand what these therapies can do. But the conference also underscored a persistent challenge. Mark van Dijk, Head of Discovery at Fairjourney Bio, told DDN that antibody technology may no longer be the main limitation. Instead, “the biology is the limitation.”